PLCOSKIN Co., Ltd. (CEO Baek Woo-yeol) will introduce ‘TissueDerm’, a medical device for soft tissue reconstruction, at ‘CES 2024’, the world’s largest IT and home appliance exhibition held in Las Vegas, USA in January.
PLCOSKIN is a bio startup that specializes in developing reconstructive medical devices capable of self-tissue regeneration, and their products are manufactured using 3D printers. Their 3D printing technology is contributing to the establishment of various methods to shorten surgery time.
Furthermore, PLCOSKIN, which has proven its ability to improve product safety and quality with a GMP-certified manufacturing facility and a 3D printer equipped there, also obtained a Class 4 medical device approval for its product from the Korea Ministry of Food and Drug Safety. This is the first achievement in Korea for a company that produces medical devices through 3D printing.
At this year’s CES, PLCOSKIN will introduce its first product, ‘TissueDerm’, a medical device for soft tissue reconstruction. This is a medical device manufactured by combining polycaprolactone (PCL) and collagen using 3D printing technology, and is used to reinforce and reconstruct the patient’s soft tissue (breast, etc.) that has defects or damage.
The collagen contained in the product is broken down in the body and replaced with autologous tissue, which in turn promotes natural tissue regeneration. In the process, it stabilizes the remaining silicone implants in the body and helps restore soft tissues to their original form before damage. Furthermore, PCL, a biodegradable polymer, gradually decomposes and disappears in the body, which has the function of solving adhesion problems that may occur when it remains in the body for a long period of time.
In addition, TissueDerm is a patient-tailored medical device made of medical composite materials and requires little pre-processing time, which can dramatically shorten surgery time. In particular, as it goes through a 3D printing production system, it also has the advantage of stable supply and demand, unlike donor tissue. Based on these characteristics that maximize the ease of reconstructive procedures, TissueDerm achieved the achievement of being selected for the Innovation Award in the Accessibility & Aging Tech category at CES 2024.
A PLCOSKIN official said, “According to the World Health Organization (WHO), as of 2020, more than 2 million new breast cancer patients occurred worldwide every year, showing an increase of about 5% every year,” and “For the treatment of breast cancer, “On average, it costs 16 million won per piece to restore the excised area, and this high cost is due to the use of donated Acellular Dermal Matirix (ADM),” he explained.
He continued, “Our company’s TissueDerm can be produced stably, which will greatly help reduce the cost of existing breast reconstruction surgery and resolve supply instability,” adding, “Sales in Korea will begin in earnest in the third quarter of this year.” “As we are targeting overseas markets next year, we expect that our participation in this CES will be of great help,” he added.
Meanwhile, ‘CES’, the world’s largest IT exhibition hosted by the Consumer Technology Association (CTA), is an exhibition that provides insight into the trends of the global home appliance industry at a glance and is held every January in Las Vegas, USA. AVING News, which has covered CES for 18 consecutive years, has reported CES news around the world every year since 2006, and has been selected through ‘BEST OF CES’ and ‘BEST OF MADE IN KOREA’, which select the best innovative products, companies and technologies. has been in progress. In addition, CES on-site issues are vividly conveyed through ‘AVING LIVE’.
The CES 2024 Seoul Unified Hall will be operated at the largest scale in terms of exhibition area, number of participating companies, and number of participating supporters since Seoul City’s first participation in CES in 2020. The Seoul Integration Center, in which 13 organizations collaborate and participate, is an important step in Seoul’s efforts to make Seoul a mecca for startups, and 17 of the companies participating in the Seoul Integration Center proved this by receiving innovation awards. The participating institutions in the Seoul Unification Center are ▲SBA ▲Seoul Bio Hub ▲Campus Town ▲AI Yangjae Hub ▲Gwanak-gu ▲Yonsei University ▲Korea University ▲Chung-Ang University ▲Sogang University ▲Kookmin University ▲Hanyang University ▲Konkuk University ▲Kyunghee University. Not only the Seoul Metropolitan Government, institutions, and companies, but also supporters through industry-academia cooperation are matched 1:1 with companies, and 85 supporters, the largest number, will participate.
* Special reporters: Joseph Choe, Kidai Kim, Dongkwan Kim, Mokkyung Lee, Sangun Choi, Seung Hyun Nam, Sunghwan Kim, Taeuck Lim, Min Choi
→ Go to the CES 2024 news special page